Clinical Development

Clinical Monitoring

Clinical research monitoring for a successful, compliant and safe clinical study.

Monitoring Your Trails On the Right Path

Located all over the world, our dedicated, professional monitoring team is the key to enhancing your study quality, improving patient safety and advancing research efficiency. All Tigermed clinical monitoring team members receive the latest new techniques and technologies via continuous training to ensure they can address any complexities in modern clinical trials.
Our clinical monitoring capabilities provide unique performance for all phases of global clinical research, including site feasibility, site start-up, site monitoring (SIV, IMV, SCV), QC and audit inspection support, remote monitoring, risk-based monitoring, etc.

CRAs around the world
Clinical trial sites in collaboration

Medical Monitoring Projects


Clinical Research Associates (CRAs)

Enabled with Senior CRAs and Master CRAs who have deep knowledge of the patients, investigative sites and specific challenges involved.

Remote monitoring experience in MCRT projects, including COVID-19 global development.

Focus on innovative drug development and experienced in Oncology, Infectious disease, Endocrinology, Vaccine, Respiratory, Hematology, CNS, Cardiovascular, Rheumatology, etc.

Our CRAs are strategically located around the world for global drug development: China Mainland, Hong Kong China, Taiwan China, Australia, Romania, United States, Mexico, Pakistan, Philippines, Malaysia, Indonesia, Laos, Argentina, Columbia, South Africa, Egypt.

All Clinical Trial Monitoring team members receive ongoing training to ensure they are completely up-to-date with current legislation, techniques and technologies.

Supported and Delivered Clinical Study of CanSino COVID-19 Vaccine

From late 2020 to early 2021, Tigermed teamed up with CanSinoBio and Pakistan local expert, as well as clinical professionals from Mexico, Russia, Chile, Argentina, to conduct Phase III trial of COVID-19 vaccine and ultimately delivered the study. This is also the first China-initiated phase III vaccine clinical study covering multiple continents, including Asia, Europe, and Latin America.

Let's Connect for a Conversation